Hvivo : Award of Share Options

For immediate release 7.00am: 16 January 2018

HVIVO PLC ("hVIVO" or the "Company")

Award of Share Options

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 15 January 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Liam Eves:

Name

Position

Number of Share Options Awarded

Exercise price per Share

Date of VestingPercentage of issued ordinary share capitalLiam Eves

Executive Vice President, Humatics

136,364

5.0p

20 December 2020

0.17%The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Liam Eves
2	Reason for the notification
a)	Position/ status	Executive Vice President, Humatics - A person closely associated with Kym Denny, Chief Executive Officer of the Company
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 5 pence each ISIN: GB00B6ZM0X53
b)	Nature of the transaction	Award of options over Ordinary Shares in the Company
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Liam EvesExercise Price (p) 5.0 Volume 136,364
e)	Aggregated information - Aggregated volume - Exercise price	136,364 options over Ordinary Shares 5.0p
f)	Date of the transaction	15 January 2018
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:
hVIVO plc	[phone]
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries	[phone]
Susan Flood (Head of Marketing)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)	[phone]
John Capodanno / Evan Smith (US)	[phone]

Notes to Editors: hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.